Education
About Us
Working with TipRanks
Follow Us
Oramed Pharmaceuticals (ORMP)
NASDAQ:ORMP
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 1.34M | $ 2.70M | $ 2.70M | $ 2.71M |
| Gross Profit | $ -193.00K | $ 1.34M | $ 2.70M | $ 2.70M | $ 2.62M |
| Operating Income | $ -12.78M | $ -15.77M | $ -40.60M | $ -24.22M | $ -11.76M |
| EBITDA | $ -14.87M | $ 7.32M | $ -36.98M | $ -25.04M | $ -11.31M |
| Net Income | $ -19.10M | $ 5.53M | $ -37.76M | $ -22.24M | $ -11.51M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 141.93M | $ 162.05M | $ 155.72M | $ 94.14M | $ 39.90M |
| Total Assets | $ 155.28M | $ 220.55M | $ 161.64M | $ 128.00M | $ 44.63M |
| Total Debt | $ 372.00K | $ 51.62M | $ 894.00K | $ 533.00K | $ 75.00K |
| Net Debt | $ -54.05M | $ 42.57M | $ -39.57M | $ -76.71M | $ -19.22M |
| Total Liabilities | $ 9.93M | $ 57.66M | $ 10.49M | $ 11.48M | $ 11.75M |
| Stockholders' Equity | $ 146.26M | $ 163.82M | $ 151.81M | $ 115.77M | $ 32.88M |
| Cash Flow | |||||
| Free Cash Flow | $ -8.43M | $ -10.55M | $ -29.20M | $ -21.56M | $ -12.52M |
| Operating Cash Flow | $ -8.41M | $ -10.29M | $ -28.70M | $ -21.18M | $ -12.44M |
| Investing Cash Flow | $ 105.82M | $ -73.04M | $ 30.21M | $ -22.26M | $ 4.63M |
| Financing Cash Flow | $ -52.04M | $ 51.98M | $ 11.56M | $ 101.39M | $ 23.79M |
Oramed Pharm Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.